ETHIC Act

Intellectual property issues including patent, copyright, and trademark issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1097 - Interagency Patent Coordination and Improvement Act of 2025. H.R.3160/S.1553 - PREVAIL Act. H.R.1574/S.708 - RESTORE Patent Rights Act of 2025. S.2276 - A bill to address patent thickets. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). H.R.3269/S.2276 - Eliminating Thickets to Increase Competition Act (ETHIC Act). USPTO Fee-Setting Authority.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $1,530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. H.R. 9681, Fair Seeds for Farmers Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act. S. 5104, Fair Seeds for Farmers Act.

Client expense: $1,710,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Client expense: $3,150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act, regarding all provisions Issues related to: - intellectual property, including amending the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees

Client expense: $2,220,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

House: H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.R. 425, the Repealing Big Brother Overreach Act H.R.7035, the Credit Card Competition Act of 2026 H.R. 6213, the Heat Workforce Standards Act of 2025 H.R. 4776, the Standardizing Permitting and Expediting Economic Development (SPEED) Act H.R. 4366, the Save Local Business Act H.R. 3898, the Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act H.R. 3699, the Energy Choice Act H.R. 4424, the Securing Help for Involuntary Employment Loss and Displacement (SHIELD) Act H.R. 5463, the Custom Health Option and Individual Care Expense (CHOICE) Arrangement Act H.R.6703, the Lower Health Care Premiums for All Americans Act H.R. 20, the Richard L. Trumka Protecting the Right to Organize (PRO) Act H.R. 4896, the Warehouse Worker Protection Act H.R. 2743, the Raise the Wage Act H.R. 1319, the Modern Worker Empowerment Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 5349, the Tax Court Improvement Act H.R. 5346, the Fair and Accountable IRS Review Act H.R.5267, the American Franchise Act H.R. 2528, the Association Health Plans Act H.R. 6420, the Affordable Care Economic Stability and Small Business (ACCESS) Act H.R.1163, the Prove It Act of 2025 H.R. 5258, the Lawsuit Abuse Reduction Act of 2025 H.R. 2675, the Protecting Our Courts from Foreign Manipulation Act of 2025 H.R. 4626, the Home Appliance Protection and Affordability Act H.R.7148 - Consolidated Appropriations Act, 2026 H.R.7328 - Protecting Small Businesses from Predatory Website Lawsuits Act H.R. 6250, the Cold Weather Diesel Reliability Act of 2025 H.R. 6453, the Americans with Disabilities Act 30 Days to Comply Act H.R.7847, the Stop Unemployment Fraud Act H.R. 2528, the Association Health Plans Act H.R. 8082, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act H.R. 6538, the More Affordable Care Act H.R. 5582, the Patients Deserve Price Tags Act H.R. 5408, the Faster Labor Contracts Act H.R.8800, National Defense Authorization Act for Fiscal Year 2027 H.R.3269, Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 5337, Motor Carrier Safety Selection Standard Act Consumer Financial Protection Bureau Section 1071 rule requires covered financial institutions to collect and report demographic and credit data on small business loan applications. H.R. 8415, Small Business Tax Cut Act H.R. 1897, Endangered Species (ES) Amendments Act of 2025 H.R.5166, Financial Services and General Government Appropriations Act, 2026 H.R. 1687, the Committing Leases for Energy Access Now (CLEAN) Act H.R. 6398, the Reducing and Eliminating Duplicative Environmental Regulations Act H.R. 8414, Know Your Labor Rights Act H.R. 7861, HSAs for All Act H.R. 7895, PBM Kickback Prohibition Act H.R. 9618, Diesel Engine Flexibility Act H.R. 9340, Ratepayer Protection Act H.R.1515, Guidance Out of the Darkness (GOOD) Act H.R. 10015, Great American Healthcare Act H.R. 5883, Safer Supervision Act of 2025 H.R. 1501, the Protecting Domestic Mining Act H.R. 9618, the Diesel Engine Flexibility (DEF) Act H.R. 10263, Halt Abusive Internet Lawsuits Act of 2026 H.R. 2675, the Protecting Our Courts from Foreign Manipulation H.J. Res. 210, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision", which would repeal an Environmental Protection Agency (EPA) rule requiring ocean-going vessels to reduce emissions while docked at California ports that increased shipping costs for energy, consumer products and inputs, and increased electricity demand and costs for small businesses and consumers. H.J. Res 213, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule issued by the Environmental Protection Agency relating to the "California State Nonroad Engine Pollution Control Standards; Commercial Harbor Craft Regulations; Notice of Decision", which would repeal the Environmental Protection Agencys (EPA) "California State Nonroad Engine Pollution Control Standards; Commercial Harbor Craft Regulations; Notice of Decision" rule which mandated that harbor vessels install more expensive zero-emissions engines. This regulation increased operating and energy costs for small businesses and consumers in California and across the country Issues relating to small business taxation Issues related to the expiring TCJA tax provisions Issues related to ADA website reforms Issues related to the minimum wage increase Issues related to "Affordable Care Act Reform" Issues related to Pharmacy Benefit Managers Issues related to Health Reform Issues related to regulatory reforms Issues related to Waters of United State Senate: S. 100, the Repealing Big Brother Overreach Act S.3623, the Credit Card Competition Act of 2026 S. 4427, Heat Workforce Standards Act of 2026 S. 3117, the Worker Reforming Elections for Speedy and Unimpeded Labor Talks (RESULTS) Act S. 3116, the Fairness in Filing Act S. 5213, the Union Members' Right to Know Act S.3124, the Protection on the Picket Line Act S.3128, the Worker Privacy Act S. 852, the Richard L. Trumka Protecting the Right to Organize (PRO) Act S. 2613, the Warehouse Worker Protection Act S. 844, the Faster Labor Contracts Act S. 2013, the Higher Wages for American Workers Act S. 1332, the Raise the Wage Act S. 1945, the Energy Choice Act S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act S.2875, the Custom Health Option and Individual Care Expense (CHOICE) Act S. 1847, the Association Health Plans Act S. 3418, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act S.495, Prove it Act of 2025 S. 3264, the More Affordable Care Act S. 2355, the Patients Deserve Price Tags Act S. 4366, Know Your Labor Rights Act S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 4419: A bill to amend title 31, United States Code, to require only foreign entities to report beneficial ownership information, and for other purposes. S.J. Res. 208, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Advanced Clean Car Program; Reconsideration of a Previous Withdrawal of a Waiver of Preemption; Notice of Decision", which would repeal an Environmental Protection Agency (EPA) waiver granted to the California Air Resources Board (CARB), allowing the continuation of the Advanced Clean Cars (ACC) framework. These overreaching standards would have resulted in a costly and unrealistic electric vehicle mandate on small business owners and consumers nationwide. S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision" which would repeal an Environmental Protection Agency (EPA) rule requiring ocean-going vessels to reduce emissions while docked at California ports. Issue relating to small business taxation S.J. Res. 206, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act Preemption for California's 2009 and Subsequent Model Year Greenhouse Gas Emission Standards for New Motor Vehicles" which would repeal an Environmental Protection Agency (EPA) rule titled California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act [CAA] Preemption for California's 2009 and Subsequent Model Year Greenhouse Gas Emission Standards for New Motor Vehicles that increased the cost of vehicles for small businesses and consumers. S.J. Res. 207, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act Preemption for California's Advanced Clean Car Program and a Within the Scope Conformation for California's Zero Emission Vehicle Amendments for 2017 and Earlier Model Years" which would repeal the Environmental Protection Agencys (EPA) waiver granting the California Air Resources Board (CARB) the authority to create the Advanced Clean Cars (ACC) framework. This overreaching rule increased costs for small businesses and consumers by creating a de facto electric vehicle mandate. S.J. Res. 205, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Small Off-Road Engines Regulations; Notice of Decision" which would repeal the Environmental Protection Agencys (EPA) rule titled "California State Nonroad Engine Pollution Control Standards; Small Off-Road Engines [SORE] Regulations. Issue related to the expiring TCJA tax provisions Issue related to ADA website reforms Issue related to the minimum wage increase Issue related to "Affordable Care Act Reform" Issue related to Pharmacy Benefits Managers Issue related to Health reform Issues related to wiretapping and eavesdropping law abuse Department of the Treasury: Beneficial Ownership Information (BOI) Reporting Rule White House: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term, Limited-Duration Insurance Plans Issues related to Health Savings Accounts Issues related to CHOICE Arrangements Healthcare Transparency Rule Vice President of the U.S.: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Department of Labor: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term, Limited-Duration Insurance Plans Occupational Safety and Health Administration: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Small Business Administration: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Title III ADA website reforms Department Health and Human Services: Short-Term, Limited Duration Insurance Rule Individual Coverage Health Reimbursement Arrangement Rule Health Savings Account Rule

Client expense: $1,910,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Occupational Safety & Health Administration (OSHA), SENATE, Small Business Administration (SBA), Treasury, Dept of, Vice President of the U.S., White House Office

S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform

Client expense: $840,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658, Medication Affordability and Patent Integrity Act Potential legislation amending the Inflation Reduction Act (P.L. 117-169) Potential legislation seeking to impose pharmaceutical price controls to private sector payers Potential legislation related to digital piracy Potential legislation relating to U.S. Copyright Office leadership Potential legislation related to changes in Patent Trial and Appeal Board Proceedings Potential legislation related to implementing most favored nation style reference pricing Potential legislation related to detection of counterfeit imports Potential legislation related to protecting consumers from counterfeit goods online Potential legislation related to the administration of federal grants and funding Various issues relating to patent examination practices and patent quality; patent filing fees and potential patent valuation fees; IP issues related to counterfeiting; pharmaceutical price controls; IP issues related to prescription drug pricing and labeling; implementation of the Inflation Reduction Act of 2022, Drug Price Negotiation Program (P.L. 117-169, subtitle B); ongoing practice of discretionary denials at the Patent Trial and Appeal Board; MFN style pricing; intellectual property and artificial intelligence; digital commercial piracy

Client expense: $16,480,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institute of Standards & Technology (NIST), Natl Telecommunications & Information Administration (NTIA), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Copyright Office, U.S. Trade Representative (USTR)

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S.2276/ H.R. 3269; Eliminating Thickets to Improve Competition Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 10575/S. 5529, the Deterring Extraterritorial Foreign Exploitation of Networks Damaging Intellectual Property (DEFEND IP) Act of 2026 S. 5104/H.R. 9681, Fair Seeds for Farmers Act H.R. 10204, Legislative Branch Agencies Clarification Act H.R 10364 American Copyright Protection Act of 2026 H.R. 10026, Honoring Circuit Judge Pauline Newman Act of 2026 H.R. 10025, Preventing Abuse of Digital Replicas Act H.R. 7140, Customer Legal Ease and Relief Act (CLEAR Act) H.R. 5811, Restoring Americas Leadership in Innovation Act of 2025 S. 3517, the Visual Artists Copyright Reform Act of 2025 H.R. 6517, To modify the appointment process for the Librarian of Congress, the Comptroller General, and the Director of the Government Publishing Office, and for other purposes H.R. 6028, Legislative Branch Agencies Clarification Act S. 1546/H.R. 3152, Patent Eligibility Restoration Act (PERA) of 2025 S. 1553/ H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) S. 1833/H.R. 3539, Leadership in CET Act S. 2677/H.R. 4930, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade S. 2455, TRAIN Act S. 2276/H.R. 3269, ETHIC Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 890, A bill to amend title 35, United States Code, to prevent double patenting, and for other purposes. H.R.1109, the Litigation Transparency Act of 2025 H.R. 2675, Protecting Our Courts from Foreign Manipulation Act of 2025 S. 1367/H.R. 5794, NO FAKES H.R 791, Foreign Anti-Digital Piracy Act (FADPA) S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 1041, Affordable Prescriptions for Patients Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 6485/S. 43, Skinny Labels, Big Savings Act Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Operations

Client expense: $10,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: Not reported

Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. S.1954, H.R.5526 - Biosimilar Red Tape Elimination Act S.1414 - Expedited Access to Biosimilars Act S.2780, H.R.5429 - Medication Affordability and Patent Integrity Act S. 2620 - Reforming Evergreening and Manipulation that Extends Drug Years Act (REMEDY Act) S.2276, H.R. 3269 - Eliminating Thickets to Increase Competition Act (ETHIC Act) S.3014 - Ensuring Timely Access to Generics Act S.43 - Skinny Labels, Big Savings Act

Client expense: $500,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues

Client expense: Not reported · Firm income: Not reported

H.R. 3269, ETHIC Act, Biopharmaceutical patent and intellectual property policy issues

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act of 2025 ---Department of Commerce Patent Valuation Fee Proposal ---Patent Litigation Reform ---Patent Tax/fees ---PTAB Reform ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China

Client expense: $2,360,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Treasury, Dept of

FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Funding for Women's Health Research ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---Program Implementation & Oversight ---Rebate Models ---SECURE 340B Act ---SUSTAIN 340B Act Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reasonable Pricing Clauses in BARDA Contracts ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---S.1414: Expedited Access to Biosimilars Act ---Biosimilars Competition (General) ---Biosimilar Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1302: Increasing Transparency in Generic Drug Application ---Access to Innovative Treatments Act ---Biosimilar Red Tape Elimination Act ---CMMI: GLOBE and GUARD Models ---CMMI Authority ---DRUG Act ---Ensuring Access to Generic Medications Act ---Ensuring Timely Access to Generics ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Medicare Drug Price Negotiation Act ---Modernizing and Ensuring PBM Accountability (MEPA) Act ---National Coverage Determination ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---Senate Finance Committee Minority RFI on Drug Pricing ---Tariffs Efforts to Expand the Bio Economy & Bio Manufacturing Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---CMMI: GLOBE and GUARD Models ---Drug Benefit Design ---International Pricing Policies ---Medicaid VBPs for Patients (MVP) Act ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---National Defense Authorization Act of 2027 National Security ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance ---Most Favored Nation Drug Pricing Proposals Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---Retaining Access and Restoring Exclusivity (RARE) Act Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Supply Chain Issues ---WHO Pandemic Preparedness Accord Precision Medicine Initiative Rare Pediatric Disease Priority Review ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---S.1816: Improving Seniors Timely Access to Care Act of 2025 ---Access to Innovative Treatments ---Administrative Rebate Rule ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicaid VBPs for Patients (MVP) Act ---Medicare Drug Price Negotiation Act ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prescription Drug Price Relief Act ---Prior Authorization Reform ---SAFE STEP Act ---Step Therapy Vaccines and Infectious Diseases ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---PASTEUR ACT ---SAFE STEP Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Modernization Act ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence

Client expense: $2,360,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, White House Office

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $870,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act.

Client expense: $1,820,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. S.1954, H.R.5526 - Biosimilar Red Tape Elimination Act S.1414 - Expedited Access to Biosimilars Act S.2780, H.R.5429 - Medication Affordability and Patent Integrity Act S. 2620 - Reforming Evergreening and Manipulation that Extends Drug Years Act (REMEDY Act) H. R. 3269 - Eliminating Thickets to Increase Competition Act (ETHIC Act) S.3014 - Ensuring Timely Access to Generics Act S.43 - Skinny Labels, Big Savings Act

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658, Medication Affordability and Patent Integrity Act S. 3822, Break Up Big Medicine Act S. 4007, Family Grocery and Farmer Relief Act Potential legislation amending the Inflation Reduction Act (P.L. 117-169) Potential legislation seeking to impose pharmaceutical price controls to private sector payers Potential legislation related to digital piracy Potential legislation related to changes in Patent Trial and Appeal Board Proceedings Potential legislation related to implementing most favored nation style reference pricing Potential legislation related to detection of counterfeit imports Potential legislation related to protecting consumers from counterfeit goods online Various issues relating to patent examination practices and patent quality; patent filing fees and potential patent valuation fees; IP issues related to counterfeiting; pharmaceutical price controls; IP issues related to prescription drug pricing and labeling; implementation of the Inflation Reduction Act of 2022, Drug Price Negotiation Program (P.L. 117-169, subtitle B); ongoing practice of discretionary denials at the Patent Trial and Appeal Board

Client expense: $16,950,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institute of Standards & Technology (NIST), Natl Telecommunications & Information Administration (NTIA), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Copyright Office, U.S. Trade Representative (USTR)

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Economic Council (NEC), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Client expense: $2,440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including amending the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,360,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 7140, Customer Legal Ease and Relief Act (CLEAR Act) H.R. 5811, Restoring Americas Leadership in Innovation Act of 2025 S. 3517, the Visual Artists Copyright Reform Act of 2025 H.R. 6517, To modify the appointment process for the Librarian of Congress, the Comptroller General, and the Director of the Government Publishing Office, and for other purposes H.R. 6028, Legislative Branch Agencies Clarification Act S. 1546/H.R. 3152, Patent Eligibility Restoration Act (PERA) of 2025 S. 1553/ H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) S. 1833/H.R. 3539, Leadership in CET Act S. 2677/H.R. 4930, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade S. 2455, TRAIN Act S. 2276/H.R. 3269, ETHIC Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 890, A bill to amend title 35, United States Code, to prevent double patenting, and for other purposes. H.R.1109, the Litigation Transparency Act of 2025 H.R. 2675, Protecting Our Courts from Foreign Manipulation Act of 2025 S. 1367/H.R. 5794, NO FAKES H.R 791, Foreign Anti-Digital Piracy Act (FADPA) S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 1041, Affordable Prescriptions for Patients Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 6485/S. 43, Skinny Labels, Big Savings Act Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Operations

Client expense: $10,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office

S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform

Client expense: $1,410,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD). The Eliminating Thickets to Increase Competition Act (ETHIC) Act (H.R. 3269), the Affordable Prescriptions for Patents Act (H.R. 1768), the Skinny Labels, Big Savings Act (H.R. 6485), the Medication Affordability and Patent Integrity Act (S. 2658), and the Ensuring Timely Access to Generics Act of 2025 (S. 3014), issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain. Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). The Drug-Price Transparency for Consumers (DTC) Act (H.R.3789), issues related to direct-to-consumer (DTC) prescription drug advertising. The Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646), issues related to funding of FDA. Issues related to the Substance Abuse and Mental Health Services Administration (SAMHSA) decision to end the use of federal funds to purchase fentanyl test strips or other substance test kits, including xylazine and medetomidine test strips, that are distributed for individual use. Issues related to mail-order access to mifepristone (generally, no specific legislation). Issues related to pharmacist deprescribing medications (generally, no specific legislation). The Medication Affordability and Patent Integrity Act, issues related to preventing manufacturers from filing inconsistent information with the Food and Drug Administration and the U.S. Patent and Trademark Office, with the intent to unfairly extend product exclusivity. The Improving Seniors Timely Access to Care Act of 2025 (H.R. 3514) and the Prior Authorization Accountability Act (H.R. 9396), issues related to prior authorization.

Client expense: $260,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,

Client expense: $99,577 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

House: H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.R. 425, the Repealing Big Brother Overreach Act H.R.7035, the Credit Card Competition Act of 2026 H.R. 6213, the Heat Workforce Standards Act of 2025 H.R. 4776, the Standardizing Permitting and Expediting Economic Development (SPEED) Act H.R. 4366, the Save Local Business Act H.R. 3898, the Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act H.R. 3699, the Energy Choice Act H.R. 4424, the Securing Help for Involuntary Employment Loss and Displacement (SHIELD) Act H.R. 5463, the Custom Health Option and Individual Care Expense (CHOICE) Arrangement Act H.R.6703, the Lower Health Care Premiums for All Americans Act H.R. 20, the Richard L. Trumka Protecting the Right to Organize (PRO) Act H.R. 4896, the Warehouse Worker Protection Act H.R. 2743, the Raise the Wage Act H.R. 1319, the Modern Worker Empowerment Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 5349, the Tax Court Improvement Act H.R. 5346, the Fair and Accountable IRS Review Act H.R.5267, the American Franchise Act H.R. 2528, the Association Health Plans Act H.R. 6420, the Affordable Care Economic Stability and Small Business (ACCESS) Act H.R.1163, the Prove It Act of 2025 H.R. 5258, the Lawsuit Abuse Reduction Act of 2025 H.R. 2675, the Protecting Our Courts from Foreign Manipulation Act of 2025 H.R. 4626, the Home Appliance Protection and Affordability Act H.R.7148 - Consolidated Appropriations Act, 2026 H.R.7328 - Protecting Small Businesses from Predatory Website Lawsuits Act H.R. 6250, the Cold Weather Diesel Reliability Act of 2025 H.R. 6453, the Americans with Disabilities Act 30 Days to Comply Act H.R.7847, the Stop Unemployment Fraud Act H.R. 2528, the Association Health Plans Act H.R. 8082, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act H.R. 6538, the More Affordable Care Act H.R. 5582, the Patients Deserve Price Tags Act H.R. 5408, the Faster Labor Contracts Act H.R.8800, National Defense Authorization Act for Fiscal Year 2027 H.R.3269, Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 5337, Motor Carrier Safety Selection Standard Act Consumer Financial Protection Bureau Section 1071 rule requires covered financial institutions to collect and report demographic and credit data on small business loan applications. H.R. 8415, Small Business Tax Cut Act H.R. 1897, Endangered Species (ES) Amendments Act of 2025 H.R.5166, Financial Services and General Government Appropriations Act, 2026 H.R. 1687, the Committing Leases for Energy Access Now (CLEAN) Act H.R. 6398, the Reducing and Eliminating Duplicative Environmental Regulations Act H.R. 8414, Know Your Labor Rights Act H.R. 8415, Small Business Tax Cuts Act of 2026 H.R. 7861, HSAs for All Act H.R. 7895, PBM Kickback Prohibition Act Issues relating to small business taxation Issues related to the expiring TCJA tax provisions Issues related to ADA website reforms Issues related to the minimum wage increase Issues related to "Affordable Care Act Reform" Issues related to Pharmacy Benefit Managers Issues related to Health Reform Issues related to regulatory reforms Senate: S. 100, the Repealing Big Brother Overreach Act S.3623, the Credit Card Competition Act of 2026 S. 4427, Heat Workforce Standards Act of 2026 S. 3117, the Worker Reforming Elections for Speedy and Unimpeded Labor Talks (RESULTS) Act S. 3116, the Fairness in Filing Act S. 5213, the Union Members' Right to Know Act S.3124, the Protection on the Picket Line Act S.3128, the Worker Privacy Act S. 852, the Richard L. Trumka Protecting the Right to Organize (PRO) Act S. 2613, the Warehouse Worker Protection Act S. 844, the Faster Labor Contracts Act S. 2013, the Higher Wages for American Workers Act S. 1332, the Raise the Wage Act S. 1945, the Energy Choice Act S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act S.2875, the Custom Health Option and Individual Care Expense (CHOICE) Act S. 1847, the Association Health Plans Act S. 3418, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act S.495, Prove it Act of 2025 S. 3264, the More Affordable Care Act S. 2355, the Patients Deserve Price Tags Act S. 4366, Know Your Labor Rights Act S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 4419: A bill to amend title 31, United States Code, to require only foreign entities to report beneficial ownership information, and for other purposes. Issue relating to small business taxation Issue related to the expiring TCJA tax provisions Issue related to ADA website reforms Issue related to the minimum wage increase Issue related to "Affordable Care Act Reform" Issue related to Pharmacy Benefits Managers Department of the Treasury: Beneficial Ownership Information (BOI) Reporting Rule H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. White House: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues relating to the right to repair Office of Management and Budget: Beneficial Ownership Information (BOI) Reporting Rule H.R.7035/S.3623, the Credit Card Competition Act of 2026 H.R. 1566/S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term Limited Duration Insurance Plans Financial Crimes Enforcement Network: Beneficial Ownership Information (BOI) Reporting Rule Department of Health and Human Services: Issues related to Individual Coverage Health Reimbursement Arrangements (ICHRA) Regulation Reform Department of Labor: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to General Health Care Reform Occupational Safety and Health Administration: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule

Client expense: $1,670,000 · Firm income: Not reported

Government targets: Financial Crimes Enforcement Network (FinCEN), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office

H.R. 3269, ETHIC Act, Biopharmaceutical patent and intellectual property policy issues

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $890,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

S. 1553 / H.R. 3160 PREVAIL Act S. 1546 / H.R. 3152 Patent Eligibility Restoration Act of 2025 (PERA) S. 1379 / H.R. 1566 REPAIR Act S. 2209 / H.R. 5155 Warrior Right to Repair Act of 2025 S. 4784 / H.R. 8800 National Defense Authorization Act S. 2658 Medication Affordability and Patent Integrity Act S. 43 / H.R. 6485 Skinny Labels, Big Savings Act S. 2276 / H.R. 3269 ETHIC Act (Eliminating Thickets to Increase Competition Act) H.R. 7015: Protecting Third Party Litigation Funding From Abuse Act S. 3826: Litigation Funding Transparency Act of 2026 H.R. 7389: Motor Vehicle Modernization Act of 2026 35 U.S.C. 5: Patent Public Advisory Committee (PPAC) and the Trademark Public Advisory Committee (TPAC) 35 U.S.C. 10: USPTO Fee-Setting Authority 15 U.S.C. 1125(d): Anti-Cybersquatting Consumer Protection Act

Client expense: $50,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)